Active, not recruitingPhase 3NCT04644575
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bioverativ, a Sanofi company
- Principal Investigator
- Clinical Sciences & OperationsSanofi
- Intervention
- efanesoctocog alfa (BIVV001)(drug)
- Enrollment
- 261 enrolled
- Eligibility
- All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- Orthopaedic Institute for Children Site Number : 8400003, Los Angeles, California, United States
- Children's Hospital Los Angeles Site Number : 8400009, Los Angeles, California, United States
- University of California San Diego Site Number : 8400007, San Diego, California, United States
- University of Florida Health Site Number : 8400008, Gainesville, Florida, United States
- Children's Healthcare of Atlanta Site Number : 8400016, Atlanta, Georgia, United States
- Rush University Medical Center Site Number : 8400010, Chicago, Illinois, United States
- Children's Hospital Of Iowa Site Number : 8400011, Iowa City, Iowa, United States
- University of Michigan Medical Center Site Number : 8400006, Ann Arbor, Michigan, United States
- Michigan State University School Of Med Site Number : 8400002, East Lansing, Michigan, United States
- Hemostasis and Thrombosis Center of Nevada Site Number : 8400001, Las Vegas, Nevada, United States
- New York Presbyterian Hospital/Weill Cornell Medical Center Site Number : 8400017, New York, New York, United States
- East Carolina University -2390 Hemby Ln Site Number : 8400015, Greenville, North Carolina, United States
- Cincinnati Children's Hospital Medical Center Site Number : 8400012, Cincinnati, Ohio, United States
- Children's Research Institute Site Number : 8400013, Columbus, Ohio, United States
- Bloodworks Northwest Site Number : 8400005, Seattle, Washington, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04644575 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06940830Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaSwedish Orphan Biovitrum
- RECRUITINGPHASE1NCT06703606A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.Pfizer
- RECRUITINGPHASE3NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AGritgen Therapeutics Co., Ltd.